Tag: FDA and Fast Track designation
![carcinoid syndrome lexicon pharmaceuticals telotristat etiprate clinical trial](https://www.carcinoid.org/wp-content/uploads/2015/08/carcinoid-syndrome-lexicon-pharmaceuticals-telotristat-etiprate-clinical-trial-300x300.jpg)
Lexicon’s Carcinoid Syndrome Treatment Meets Primary Endpoint in Phase III Clinical Trial
August 5, 2015
Lexicon Pharmaceuticals Inc. has announced that the pivotal phase III clinical trial, TELESTAR, of its oral drug candidate telotristat etiprate met the primary endpoint in treating cancer patients with carcinoid syndrome that is not adequately controlled…
READ MORE